3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
75
Neoplasms
15
Neoplasm Metastasis
9
Advanced Breast Cancer
5
Neoplasms by Site
3
Breast Diseases
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Patient Compliance
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases
1
Recurrence
1
Quality of Life
1
Osteoporosis
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Joint Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Cancer Metastatic
1
Bone Diseases, Metabolic
1
Bone Density
1
Arthralgia
1
Advanced Metastatic Breast Cancer
1
Interventions
Trastuzumab
3
Docetaxel
3
Gemcitabine
2
tusamitamab ravtansine
1
nirogacestat
1
margetuximab
1
exemestane
1
Vinorelbine
1
Tamoxifen
1
Letrozole
1
Fulvestrant
1
Capecitabine
1
Anastrozole
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Cancer Metastatic
×
Anastrozole
×
Clear all
NCT04059484
2026-02-24
AMEERA-3
Sanofi
Phase 2
Terminated
367 enrolled
30 charts